Skip to main content
. 2020 Jan 16;5(1):e121781. doi: 10.1172/jci.insight.121781

Figure 1. miRNA expression profiles in BM of MF patients differ according to ruxolitinib treatment responsiveness, specifically for miR-543 levels.

Figure 1

(A) Heatmap displaying the microRNAs most differently expressed in nonresponders (0%–24% spleen size reduction after ruxolitinib treatment; n = 7) compared with responders (100% or complete elimination of palpable splenomegaly after ruxolitinib treatment; n = 7). Color key represents normalized expression values, where, for each row, red represents the maximum expression value and green the lowest. (B) Differential expression of miR-543 according to responsiveness to ruxolitinib treatment was validated by RT-qPCR in the same cohort of patients (cohort 1). (C) miRNA network analysis of the miRNA array profile from responders (n = 7) and nonresponders (n = 7). (D) Differential expression of miR-543 was further measured by RT-qPCR in an independent cohort of healthy controls (n = 9) and untreated patients with MF (n = 11) (cohort 2). (E) Differential expression of miR-543 was also measured by RT-qPCR in an independent cohort of healthy controls (n = 7) and untreated patients with MF (n = 16) (cohort 3). Nonresponder patients are identified with red triangles and responders with blue circles. Two-tailed t test was used to assess statistical significance for B, D, and E. Each dot represents 1 human sample. All experiments were repeated independently 3 times.